Skip to content
Call Us:+251 98 037 8072
Call Us:+251 98 037 8072
Ethiopia’s Pharmaceutical Market in 2026: Size, Growth and Import Dependence in Numbers
Leave a Comment（https://ethiolifecare.com/ethiopia-pharmaceutical-market-size/#respond） / Insights（https://ethiolifecare.com/category/insights/） / By admin（https://ethiolifecare.com/author/admin/）
Ethiopia imported US$677.9 million worth of pharmaceutical products under HS chapter 30 in 2023, according to UN Comtrade data published through the World Bank’s WITS platform. That is the clearest, most independently checkable figure for the size of the country’s medicine trade, and a steadier starting point than the market-size estimates circulating in investor decks and blog posts, several of which trace back to a single 2019 slide.
This post works through what is actually known about Ethiopia’s pharmaceutical market: its size, the widely repeated “85% imported” claim, how many companies manufacture medicine here, what the public buyer spends, and how Ethiopia’s import bill compares with its neighbours once population is accounted for. Every number is dated and sourced. Where credible sources disagree, both are shown rather than one being quietly dropped.
What the market is actually worth, and why the estimates disagree
Every public figure for the size of Ethiopia’s pharmaceutical market traces back to one of two sources, both now a decade or closer to a decade old.
The first is the WHO’s National Strategy and Plan of Action for Pharmaceutical Manufacturing Development in Ethiopia, 2015-2025（https://cdn.who.int/media/docs/default-source/medicines/local-production/ethiopia-strategy-local-poduction.pdf）, launched July 2015. It put the annual market at US$400-500 million, growing roughly 25% a year, based on a February 2015 estimate from the then Pharmaceuticals Fund and Supplies Agency, and cites a separate 2012 Frost & Sullivan forecast of “slightly over 14%” annual growth reaching just under US$1 billion by 2018.
The second is a page on the Ethiopian Investment Commission’s website（https://investethiopia.gov.et/key-sectors/manufacturing/pharmaceuticals/）, stating that “Ethiopia’s domestic market for pharmaceutical products is estimated at US$1 billion,” growing 15% a year, projected to reach US$1.8 billion in 2025 and US$4 billion in 2030, cited directly to a “Frost & Sullivan and World Bank… PowerPoint presentation (2019).” The page also states Ethiopia’s population as 116 million, closer to 2019-2020 levels than the World Bank’s current ~132 million, evidence it has not been refreshed since.
Estimate Value Growth quoted Data vintage
WHO 2015 strategy (PFSA estimate) US$400-500 million/year ~25%/year 2014/15
Frost & Sullivan, cited in the same WHO document ~US$1 billion by 2018 ~14%/year 2012 forecast
Ethiopian Investment Commission (current page) ~US$1 billion “currently”; US$1.8bn by 2025; US$4bn by 2030 ~15%/year Sourced to a 2019 presentation Source: WHO National Strategy and Plan of Action for Pharmaceutical Manufacturing Development in Ethiopia, 2015-2025; investethiopia.gov.et, pharmaceuticals sector page. No independently audited, current total-market figure turned up in this research. Anyone quoting a single dollar figure for “Ethiopia’s pharmaceutical market” in 2026 is quoting one of the two lineages above, usually without saying so.
The trade data: what Ethiopia actually paid for imported medicine, year by year
UN Comtrade（https://comtradeplus.un.org/） tracks import value for HS chapter 30, pharmaceutical products, by reporting country. Ethiopia’s 2015-2017 figures are recorded at implausibly small amounts, almost certainly a classification gap, so the usable series starts in 2018. UN Comtrade, HS 30 (pharmaceutical products), reporter Ethiopia, partner World, 2018-2023. The value climbed from US$690.2 million in 2018 to a peak of US$812.0 million in 2021, then fell for two straight years to US$677.9 million in 2023. The 2021 spike and subsequent pullback line up with events unrelated to underlying demand: elevated pandemic-era health spending, then the forex shortage that tightened import permits from 2022 through the National Bank’s move to a market-based exchange rate in July 2024（https://ethiolifecare.com/birr-exchange-rate-medicine-prices-ethiopia-2026/）. The fall looks more like constrained access to foreign currency than weaker demand.
A narrower, more recent figure comes from customs-data provider NBD, which put Ethiopia’s pharmaceutical imports at US$160.95 million for H1 2025 (January-June) across more than 1,200 transactions, rising from US$24.63 million in January to US$31.93 million in June. Annualised, that points to roughly US$320-350 million for the full year, well below the Comtrade range above. The gap could reflect lower volumes after the 2024 exchange-rate reform, narrower product coverage in NBD’s data than in the full HS 30 chapter, or both, and the data cannot yet separate the two.
NBD’s H1 2025 data names India as the leading supplier at US$68.3 million across 577 transactions, followed by Belgium (US$34.0 million), China (US$15.6 million), Turkey (US$6.4 million) and Kenya (US$3.48 million).
The “85% imported” figure: where it actually comes from
A specific claim shows up across investor material and secondary blogs: that 85% (sometimes rounded to 90%) of Ethiopia’s pharmaceutical supply is imported. It has a traceable source: the same Ethiopian Investment Commission page states, next to the US$1 billion market-size figure above, “Currently, 85% of pharmaceutical supply in Ethiopia is imported, a big gap that is yet to be filled by local production,” sourced to the same 2019 Frost & Sullivan/World Bank presentation.
That 2019 figure is itself one step removed from a 2014/15 WHO estimate that put local manufacturers’ share of the market at about 20%, meaning roughly 80% imported. The number has been in circulation, essentially unchanged, for over a decade: a March 2026 peer-reviewed paper on manufacturing compliance still opens by citing Ethiopia’s “85% reliance on imported drugs” with no fresh source.
Meanwhile, the most recent figure from an authoritative source points a different direction. The World Bank reported in May 2026（https://www.worldbank.org/en/news/feature/2026/05/26/building-ethiopia-s-pharmaceutical-future-from-strong-regulation-to-local-production） that local production “now exceeds 40% of medicine supply,” attributed to Heran Gerba, against the national target, as the same feature frames it, of covering 50% of essential-medicine demand domestically, a genuinely different picture from “85% imported.”
The two figures are not necessarily contradictory once scope is accounted for. “Medicine supply” in the World Bank’s framing likely spans the fuller range of locally made health products, including the disposables and consumables several Ethiopian manufacturers (LifeCare’s own Gulele facility among them, producing hand sanitiser, gauze bandages, glycerine and denatured alcohol) supply alongside finished pharmaceuticals. Sources specific to finished dosage forms, covered next, tell a more modest story. Addis Fortune (Oct 2024); PLOS Global Public Health (2021/22 consumption data, published Dec 2025); World Bank (2026). How many companies actually make medicine here
The manufacturer count has grown, but slowly, and depends on who is counting and what they count. The 2015 WHO strategy document counted approximately 200 importers alongside a local industry of 22 suppliers and manufacturers, nine of which directly manufactured pharmaceutical products, supplying about 20% of the local market and only 90 of the more than 380 medicines on the national essential medicines list.
A peer-reviewed study published in PLOS Global Public Health in December 2025（https://doi.org/10.1371/journal.pgph.0005631）, based on fieldwork carried out from October 2021 to February 2022, counted “only eleven active local pharmaceutical manufacturing companies” in Ethiopia, against 38 in Kenya. The same study found that local manufacturers, calculated against 2021/22 medicine consumption, covered 15-20% of national pharmaceutical needs, that capacity utilisation sat under 50%, that only three manufacturers fully complied with current Good Manufacturing Practice (cGMP) standards, and that over 90% of local production’s own raw materials were imported.
A more recent snapshot, from Addis Fortune, October 2024（https://addisfortune.news/pharmas-export-ambitions-meet-regulatory-capacity-hiccups）, quoted Africure Pharmaceuticals CEO Tadesse Teferi describing “the current 14 local manufacturers” as struggling “to meet a mere eight to 12pc of domestic demand, operating at only 20pc capacity,” with local share of total pharmaceutical stock “less than 12pc, down from 25pc during their prime.” The same article named five GMP-certified manufacturers, up from the three PLOS found two years earlier. A separate December 2024 piece describes the sectoral association as representing 24 members（https://addisfortune.news/tag/ethiopian-pharmaceuticals-medical-supplies-manufacturing-association-epmsma）, a wider figure likely spanning medical supplies producers too.
A March 2026 study in PLOS One（https://doi.org/10.1371/journal.pone.0343881） put the number of “large-scale pharmaceutical manufacturers” at 12, and assessed cGMP compliance at six directly: rates ranged from 62.8% to 86.7%, with only one company showing critical deviations.
Source Count Data year
WHO strategy document 9 manufacturers (22 local suppliers/manufacturers total) 2014/15
PLOS Global Public Health 11 active manufacturers (vs. 38 in Kenya) fieldwork 2021/22
PLOS One 12 large-scale manufacturers 2024/25
Addis Fortune, quoting industry CEO 14 local manufacturers Oct 2024
EPMSMA sectoral association membership 24 members (broader scope) Dec 2024 Source: WHO 2015 strategy PDF; PLOS Global Public Health, doi 10.1371/journal.pgph.0005631; PLOS One, doi 10.1371/journal.pone.0343881; Addis Fortune, October and December 2024. EPSS: the public buyer’s footprint
The Ethiopian Pharmaceuticals Supply Service is the dominant public purchaser of medicines.